Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUC-MSC for Cerebral Hemorrhage Sequela
NCT02283879Phase 1Unknown
- Sponsor
- Shenzhen Hornetcorn Biotechnology Co., Ltd.
- Start
- Mar 2015
- Primary completion
- Dec 2016
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of human umbilical cord mesenchymal stem cells in cerebral hemorrhage, sponsored by Shenzhen Hornetcorn Biotechnology Co., Ltd. Primary endpoint: Safety evaluation through vital signs, clinical lab tests and adverse events at 12 months. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
cerebral hemorrhage
Beyond the preview
Go deeper on NCT02283879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02283879.